HMPV: Not Likely to Become the Next Global Pandemic, Says UGM Expert
Health & Wellness
YOGYAKARTA, Indonesia — Professor Tri Wibawa, Dean of the Faculty of Medicine, Public Health, and Nursing at Universitas Gadjah Mada (UGM), has reassured the public that Human Metapneumovirus (HMPV) is unlikely to cause the next global pandemic.
"HMPV has a much lower risk of becoming fatal compared to SARS-CoV-2, and it’s less likely to cause a pandemic," Professor Tri said in an interview in Yogyakarta on Thursday.
Unlike SARS-CoV-2, which can affect people of all ages, HMPV primarily targets children and those with weakened immune systems. "HMPV has been circulating worldwide for a long time and is believed to have infected everyone in their childhood," Tri explained.
First identified in 2001, HMPV is now confirmed to be a known strain by Chinese authorities. While it shares some similarities with SARS-CoV-2, causing respiratory symptoms such as coughing, sneezing, and sore throat, it’s less virulent.
Professor Tri warns that while HMPV is common, certain groups are more at risk: children, the elderly (over 65), and those with lung conditions. He advises maintaining good health habits — eating well, staying hydrated, and getting enough rest — to boost immunity.
Regular handwashing, wearing a mask if you have respiratory symptoms, and avoiding close contact with those who might be infected are crucial. "These measures are important as there’s still no vaccine for HMPV," Tri said.
In conclusion, although HMPV is similar to influenza, it’s not expected to cause a global pandemic. However, everyone should remain vigilant and practice good hygiene to protect themselves from potential infections.
Worth a look
- Simple Daily Exercise to Ease Back Pain
- How Interferon-Alpha Treats Rare Blood Cancers: New Study Findings
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)